Alex Slowey, Kindeva Drug Delivery - Qepler Summits And Conferences

Alex Slowey

Formulation Specialist
Kindeva Drug Delivery
Leicester, United Kingdom
Kindeva are the experts in complex drug delivery—solving the most complex challenges and offering end-to-end capabilities.

Alex Slowey is qualified as a Pharmacist in July 1997, and have over 20 years experience in the pharmaceutical industry.

"I like to be challenged and to work proactively to innovate and find novel solutions where existing limitations prevent progress."

Since November 1997, he have held various roles within the R&D function at 3M Health Care, which have given him a broad footing in the pharmaceutical industry, particularly in relation to the research and development activities required to get a new product from initial feasibility to registration.

Alex is specialised in early phase development activities related to the formulation of new molecules for nasal and pulmonary delivery.

Alex has significant expertise in a number of key areas, these include providing technical and project leadership to development programmes.

Alex has developed expertise in particle engineering, with direct application to the delivery of molecules by the pulmonary route via pMDIs and DPIs.

Areas of interest include spray drying, freeze drying and powder blending.

Alex also has clinical expertise, particularly with respect to clinical trials of metered dose inhalers.

Alex takes an active role on the steering committee of the international Drug Delivery to the Lungs Conference.

Alex has supervised a PhD project looking at the use of novel excipients with a view to formulating a stable insulin system for pulmonary delivery.

Particle engineering.
Formulation of pressurised metered dose inhalers and dry powder inhalers.
MDI clinical studies.

Related Sessions:

Inhaled Drug Delivery
Summit 2019

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 23 May 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 23 May 2019
CASE STUDY: An approach to developing existing pulmonary API’s into adjacent dosage forms and understanding the in-vitro / in-vivo relationship..
  • There is currently no ‘holy grail’ in accurately correlating in-vitro performance with clinical outcomes when developing new metered dose inhaler products.
  • To successfully develop inhaled medicines for the treatment of lung diseases such as asthma and COPD, the use of more clinically relevant in-vitro testing is necessary.
  • By their use, and growing understanding, appropriate in-vitro techniques can be used as a predictive tool for in-vivo outcomes.
View Details

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 2: Friday, 06 August 2021
CASE STUDY: To Be Announced.
View Details